May 22, 2017

New GB Sciences board vice chair announced


Bocskor Small Image

Bocskor Appointed Board Vice Chair

LAS VEGAS, May 22, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB:GBLX) is pleased to announce the appointment of Mr. Leslie Bocskor as Vice Chairman, effective April 28, 2017.  John Poss remains Chairman of the Board and CEO.

Bocskor has been a director of GB Sciences ("the Company") since May 2016, and in this role has been instrumental in the Company's capital formation process and in the Company's relationship with its investment bank, Network 1.  Network 1 has raised over $14 million to fund GB Sciences' further growth and investments.  Bocskor also brought Shane Terry to the Board of Directors.  Mr. Terry is an independent consultant who provides advisory services to Medical Marijuana Establishments (MME's) in Nevada and other states.  With Bocskor's focus on shareholder value in building a biopharma and life sciences powerhouse with strong IP, innovative research programs, and technology, he brings a broad understanding of the future of cannabis markets, investment banking, and cannabis policy.

"Leslie's leadership and vision within our industry has been invaluable in helping us stay ahead of the changes in the industry and to properly leverage the assets of our Life Sciences Division throughout the value chain," said John Poss, GB Sciences CEO and Chairman of the Board.

"I'm honored to be in a role where I can serve industry and science by changing people's lives and by changing the way in which cannabis innovation in medicine is brought to market.  I'm incredibly encouraged by the strides that we have already made with GB Sciences in advancing the state of biomedical research in cannabis for human health. I look forward to contributing more guidance for continued success," stated Bocskor.

About GB Sciences, Inc. GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.  The Company's goal is creating safe, standardized, cannabinoid therapies that target a variety of medical conditions.  To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

About Leslie Bocskor, Electrum Partners Leslie Bocskor with his advisory firm, Electrum Partners, is leading the evolving discussion around policy, entrepreneurship, and investment in the cannabis industry, nationally and internationally.  As founding chairman of the Nevada Cannabis Industry Association, and with his far-reaching Wall Street background, he's helping design the models for cannabis industry investment, business, and regulation. Bocskor's insights and influence have made him the trusted expert and revered pundit on the future of the cannabis marketplace.

Forward-Looking Statements This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements.  These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information Corporate: GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118 866-721-0297, or  Liz Bianco Publicity Director, liz@gbsciences.com, http://gbsciences.com Investors: John Poss, j.poss@gbsciences.com 

SOURCE GB Sciences, Inc.